Testing OPT101 for type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests an investigational drug called OPT101 in people with type 1 diabetes. It aims to see how the drug works in the body and whether it can help preserve insulin production, especially in those diagnosed recently or within the last 20 years.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 50 years old.
- You have been diagnosed with type 1 diabetes (within the last 20 years for one part, or less than 10 years for another part).
- You are willing to wear a continuous glucose monitor (like a FreeStyle Libre 3) during the study.
- You do not have serious kidney, liver, or blood clotting problems, and you are generally in good health.
- You have not had cancer (except certain skin cancers) or a weakened immune system.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication that may help your body respond better to insulin. It's for people with type 1 diabetes who use an automated insulin pump and are willing to take a daily pill for 12 weeks.
This trial is testing a one-time cell treatment (CARC-101C) for people recently diagnosed with type 1 diabetes. The goal is to see if it is safe and can help preserve the body's ability to make some insulin.
This trial tests a new continuous glucose monitor (CGM) designed to help manage blood sugar levels. You will wear the device for 15 days and attend three clinic visits to see how well it works.
This trial tests a new study drug called CNP-103 for people ages 12-35 who were recently diagnosed (within 6 months) with stage 3 type 1 diabetes. The goal is to see if the drug can help preserve the body's ability to make some insulin, potentially slowing the need for more insulin shots.
This study tests a new automated insulin delivery system to help people with type 1 diabetes better manage their blood sugar. It aims to see if the system improves glucose control safely.
This study tests a new medication, MTX228, to see if it can help people with type 1 diabetes who still make some insulin. It may slow the loss of your own insulin production and improve blood sugar control.
Hear when a new Type I Diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.